Compare Enbridge Inc (ENB) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enbridge Inc vs 10X Genomics Inc — how do they compare? Enbridge Inc trades at $51.64 (market cap $112.62B), while 10X Genomics Inc trades at $57.7 (market cap $7.61B). The key difference: Enbridge Inc is far larger — about 14.8× 10X Genomics Inc's market cap, and Enbridge Inc pays a 5.34% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals.
| ENB | TXG | |
|---|---|---|
Market Cap | $112.62B | $7.61B |
Sector | Energy | Health |
52-Week High | $58.04 | $58.57 |
52-Week Low | $45.23 | $11.34 |
Enterprise Value | $196.53B | $7.14B |
Dividend Yield | 5.34% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENB trades at $51.49, up 0.19% on the day, with a mixed technical picture showing bearish moving averages but oversold RSI levels. The company reported Q2 2026 EPS of $0.46, beating estimates of $0.43, and maintains a strong dividend yield with 31 consecutive years of increases. Revenue for 2025 reached $65.19B, with net income of $7.49B, though profit margins have fluctuated. Analyst consensus is evenly split between Buy and Hold ratings.
Outlook is stable with growth supported by a $41B project backlog and utility demand, but risks include regulatory challenges like pipeline disputes and high debt levels. The stock offers income appeal through dividends, yet faces headwinds from energy market volatility and legal uncertainties.
TXG trades at $57.77, down 1.37% today, with a bullish technical outlook supported by moving averages and strong support at $55. The company shows improving fundamentals with Q2 2026 earnings beating estimates and positive cash flow trends, though it remains unprofitable with negative margins. Recent news highlights collaborations with major medical institutions and strategic acquisitions expanding multiomics capabilities.
Investment outlook is mixed: technical strength and analyst upgrades suggest near-term upside potential, but high valuation multiples and persistent losses pose significant risks. The stock faces pressure from competitive threats and execution challenges in achieving profitability, requiring careful monitoring of upcoming Q3 earnings and revenue growth sustainability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Enbridge Inc
Enbridge owns extensive midstream assets that transport hydrocarbons across the U.S. and Canada. Its pipeline network consists of the Canadian Mainline system, regional oil sands pipelines, and natural gas pipelines. The company also owns and operates a regulated natural gas utility and Canada's largest natural gas distribution company. Finally, the firm has a small renewables portfolio primarily focused on onshore and offshore wind projects.
Read more on ENB →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
